Atossa Therapeutics, Inc.
$6.17
▲
4.99%
2026-04-21 05:28:00
www.atossatherapeutics.com
NCM: ATOS
Explore Atossa Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$50.2 M
Current Price
$6.17
52W High / Low
$19.35 / $3.76
Stock P/E
—
Book Value
$4.57
Dividend Yield
—
ROCE
-94.38%
ROE
-62.74%
Face Value
—
EPS
$-4.04
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
16
Beta
1.34
Debt / Equity
—
Current Ratio
5.53
Quick Ratio
5.53
Forward P/E
-1.45
Price / Sales
—
Enterprise Value
$1.24 M
EV / EBITDA
-0.03
EV / Revenue
—
Rating
Strong Buy
Target Price
$43.75
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Creative Medical Technology Holdings, Inc. | $2.26 | — | $9.13 M | — | -81.64% | -86.47% | $6.25 / $1.5 | $2.03 |
| 2. | IN8bio, Inc. | $1.5 | — | $14.77 M | — | -68.2% | -92.49% | $5.82 / $1.17 | $2.82 |
| 3. | Alaunos Therapeutics, Inc. | $2.84 | — | $6.71 M | — | -233.25% | -1.98% | $6.2 / $1.67 | $1.27 |
| 4. | Silence Therapeutics plc | $7.93 | — | $349.74 M | — | -76.17% | -90.27% | $2.6 / $0.5 | $1.32 |
| 5. | Summit Therapeutics Inc. | $24.32 | — | $18.91 B | — | -161.37% | -2.06% | $36.91 / $13.83 | $0.85 |
| 6. | XORTX Therapeutics Inc. | $2.25 | — | $4.16 M | — | -156.2% | -98% | $9.85 / $2.42 | $0.3 |
| 7. | Scholar Rock Holding Corporation | $47.8 | — | $5.49 B | — | -110.26% | -1.23% | $51.62 / $27.07 | $2.26 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -11.44 M | -9.25 M | -9.04 M | -7.41 M | -7.15 M | — |
| Net Profit | -10.94 M | -8.69 M | -8.42 M | -6.72 M | -6.35 M | — |
| EPS in Rs | -1.27 | -1.01 | -0.98 | -0.78 | -0.74 | -0.9 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -37.14 M | -27.62 M | -31.38 M | -27.69 M |
| Net Profit | -34.77 M | -25.5 M | -30.09 M | -26.96 M |
| EPS in Rs | -4.04 | -2.96 | -3.49 | -3.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 47.61 M | 76.44 M | 96.25 M | 123.53 M |
| Total Liabilities | 8.26 M | 4.97 M | 5.24 M | 5.57 M |
| Equity | 39.35 M | 71.48 M | 91.02 M | 117.96 M |
| Current Assets | 45.62 M | 74.46 M | 92.22 M | 118.2 M |
| Current Liabilities | 8.26 M | 4.97 M | 5.24 M | 5.57 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -29.76 M | -21.03 M | -20.94 M | -20.76 M |
| Investing CF | -0.02 M | -0.02 M | -0.01 M | -4.73 M |
| Financing CF | 0 M | 3.67 M | -1.48 M | 0 M |
| Free CF | -29.79 M | -21.05 M | -20.95 M | -20.79 M |
| Capex | -0.02 M | -0.02 M | -0.01 M | -0.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -36.33% | 15.25% | -11.62% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-02-02 | 1:0.0666667 |